首页> Journal of the European Academy of Dermatology and Venereology : JEADV> Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.

导出 OA

翻译打印收藏纠错

第一作者： A,Blauvelt

第一单位： Oregon Medical Research Center, Portland, OR, USA.

作者： A,Blauvelt ^[1] ; K,Reich ^[2] ; S,Mehlis ^[3] ; F,Vanaclocha ^[4] ; H,Sofen ^[5] ; W,Abramovits ^[6] ; Y,Zhao ^[7] ; I,Gilloteau ^[8] ; E,Davenport ^[9] ; N,Williams ^[9] ; A,Guana ^[10] ; S,Tyring ^[11]

作者单位： Oregon Medical Research Center, Portland, OR, USA. ^[1] Dermatologikum Hamburg and SCIderm GmbH, Hamburg, Germany. ^[2] NorthShore University Health System, Skokie, IL, USA. ^[3] Dermatology Department, Hospital Universitario, Madrid, Spain. ^[4] Department of Medicine (Dermatology) UCLA, Los Angeles, CA, USA. ^[5] Baylor University Medical Center, Dallas, TX, USA. ^[6] Formerly with Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. ^[7] Novartis Pharma AG, Basel, Switzerland. ^[8] RTI Health Solutions, Research Triangle Park, NC, USA. ^[9] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. ^[10] University of Texas Health Science Center for Clinical Studies, Houston, TX, USA. ^[11]